# Techniques for Validating CRISPR Changes Using RNA-Sequencing Data

**Authors:** Susan K. Rathe, Tracy A. Marko, Elizabeth N. Edwards, Paige Hazelton Ridder, Jyotika Varshney, Kyle B. Williams, James E. Johnson, Branden S. Moriarity, David A. Largaespada

PMC · DOI: 10.3390/genes16040369 · 2025-03-24

## TL;DR

This paper shows how RNA-sequencing can reveal unexpected changes caused by CRISPR gene editing that DNA-based methods miss.

## Contribution

The study introduces RNA-seq-based techniques to detect unintended CRISPR effects like fusions and exon skipping.

## Key findings

- RNA-seq identified inter-chromosomal fusions and exon skipping not seen with DNA methods.
- Unintended transcriptional changes in neighboring genes were detected in CRISPR experiments.
- Guidelines are provided for using RNA-seq to validate CRISPR modifications comprehensively.

## Abstract

The use of CRISPR to knockdown or knockout genes is a powerful tool for understanding the specific role of a gene in disease development. However, it can cause many unanticipated changes to the transcriptome that are not detected by DNA amplification and Sanger sequencing of the target site. Various RNA-sequencing techniques can be used to identify these changes and effectively gauge the full impact of the CRISPR knockout, thereby providing a means of selecting appropriate clones for further experimentation. Background/Objectives: RNA-seq data from 4 CRISPR knockout experiments were analyzed and techniques developed to both confirm the success of the CRISPR modifications and identify potential issues. Methods: A broad-based analysis of RNA-sequencing data identified many CRISPR-based changes not identified by PCR amplification of DNA around the CRISPR target site. These changes included an inter-chromosomal fusion event, exon skipping, chromosomal truncation, and the unintentional transcriptional modification and amplification of a neighboring gene. Conclusions: The inadvertent modifications identified by the evaluation of 4 CRISPR experiments highlight the value of using RNA-seq to identify transcriptional changes to cells altered by CRISPR, many of which cannot be recognized by evaluating DNA alone. Specific guidelines are presented for designing and analyzing CRISPR experiments using RNA-seq data.

## Full-text entities

- **Genes:** NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}, SRGAP2B (SLIT-ROBO Rho GTPase activating protein 2B) [NCBI Gene 647135] {aka SRGAP2L, SRGAP2P2}, SUZ12 (SUZ12 polycomb repressive complex 2 subunit) [NCBI Gene 23512] {aka CHET9, IMMAS, JJAZ1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, SRGAP2 (SLIT-ROBO Rho GTPase activating protein 2) [NCBI Gene 457680], GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, EED (embryonic ectoderm development) [NCBI Gene 8726] {aka COGIS, HEED, WAIT1}, SRGAP2C (SLIT-ROBO Rho GTPase activating protein 2C) [NCBI Gene 653464] {aka SRGAP2P1}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, ZNF776 (zinc finger protein 776) [NCBI Gene 284309], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, SRGAP2D (SLIT-ROBO Rho GTPase activating protein 2D (pseudogene)) [NCBI Gene 100996712], POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, UTP6 (UTP6 small subunit processome component) [NCBI Gene 55813] {aka C17orf40, HCA66}, CHN1 (chimerin 1) [NCBI Gene 1123] {aka ARHGAP2, CHN, DURS2, NC, RHOGAP2}, SRGAP2 (SLIT-ROBO Rho GTPase activating protein 2) [NCBI Gene 23380] {aka ARHGAP34, FNBP2, SRGAP2A}
- **Diseases:** KO (OMIM:615441), deficient (MESH:D007153), Chromosome 7 deletion (MESH:C537814), metastasis (MESH:D009362), Osteosarcoma (MESH:D012516), injury to (MESH:D014947), Chromosome 13 deletion (MESH:D000073839), Chromosome 18 deletion (MESH:C536580), IGV (MESH:D000081042), OS (MESH:C567932)
- **Chemicals:** penicillin (MESH:D010406), Puromycin (MESH:D011691), ATTCs (-), SYBR green (MESH:C098022), PBS (MESH:D007854), PVDF (MESH:C024865), doxycycline (MESH:D004318), NaCl (MESH:D012965), Bis-Tris (MESH:C026272), streptomycin (MESH:D013307), NP-40 (MESH:C010615), EDTA (MESH:D004492), NaF (MESH:D012969), Giemsa (MESH:D001399), colcemid (MESH:D003703), xenon (MESH:D014978), NEON (MESH:D009356)
- **Species:** Homo sapiens (human, species) [taxon 9606], Escherichia coli (E. coli, species) [taxon 562], Mus musculus (house mouse, species) [taxon 10090], Pan troglodytes (chimpanzee, species) [taxon 9598]
- **Mutations:** S12, R477*
- **Cell lines:** 143B — Homo sapiens (Human), Osteosarcoma, Cancer cell line (CVCL_2270), HSC1lambda — Homo sapiens (Human), Skin squamous cell carcinoma, Cancer cell line (CVCL_2807), KO7 — Cricetulus griseus (Chinese hamster), Spontaneously immortalized cell line (CVCL_H340), SKOV3 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_0532), HEY — Homo sapiens (Human), High grade ovarian serous adenocarcinoma, Cancer cell line (CVCL_0297), N23 — Cricetulus griseus (Chinese hamster), Spontaneously immortalized cell line (CVCL_K265)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12027141/full.md

---
Source: https://tomesphere.com/paper/PMC12027141